Scienture Holdings, Inc.
SCNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SCNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCNX
Scienture Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing branded products for CNS and CVS diseases, with two launched products and a pipeline of candidates in clinical development.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Scienture Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing branded products for CNS and CVS diseases, with two launched products and a pipeline of candidates in clinical development.
- Scienture has two commercial products launched (Arbli™ and REZENOPY™) and three primary product candidates in its development pipeline [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash of $8.2M, total revenue of $0.3M, net income of -$2.8M, and shareholders' equity of $79.1M [sec].
- The company had an accumulated deficit of $86,775,872 as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Scienture's pipeline includes SCN-106 (Alteplase) and SCN-104 (DHE), with R&D expenses of $1,166,605 for the three months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Management has expressed substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued [sec_mda · as of 2026-08-13].
What works
- Scienture has two FDA-approved products (Arbli™ and REZENOPY™) already launched, providing initial commercial revenue [sec_mda · as of 2026-08-13].
- The company's pipeline targets CNS and CVS diseases, with multiple candidates in clinical development, suggesting a diversified approach [sec_mda · as of 2026-08-13].
- Cash increased from $6.66M (Dec 31, 2025) to $8.19M (June 30, 2026), indicating improved liquidity [sec_mda · as of 2026-08-13].
What to weigh
- The company has an accumulated deficit of $86.8M as of June 30, 2026, reflecting ongoing losses [sec_mda · as of 2026-08-13].
- Management has raised substantial doubt about the company's ability to continue as a going concern within one year [sec_mda · as of 2026-08-13].
- Revenue is limited ($0.3M for six months ended June 30, 2026), and the company expects to need additional capital to fund operations [sec_mda · as of 2026-08-13].
- R&D expenses are increasing as pipeline candidates advance, putting pressure on cash resources [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Scienture has two commercial products and three primary product candidates.
“We currently has two commercial products that have been launched and three primary product candidates in our development pipeline”
SEC MD&A · August 13, 2026
The company had an accumulated deficit of $86.8M as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $86,775,872.”
SEC MD&A · August 13, 2026
Management has substantial doubt about going concern.
“that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has expressed substantial doubt about the company's ability to continue as a going concern within one year [sec_mda · as of 2026-08-13].
- Limited revenue and high losses — Revenue is only $0.3M for six months ended June 30, 2026, with an accumulated deficit of $86.8M [sec] [sec_mda · as of 2026-08-13].
- Need for additional capital — The company will need to raise additional capital to fund operations, which may not be available on favorable terms [sec_mda · as of 2026-08-13].
- Pipeline development costs — R&D expenses are increasing as pipeline candidates advance, potentially straining cash resources [sec_mda · as of 2026-08-13].
What to watch
- Commercial ramp of Arbli™ and REZENOPY™ revenue generation [sec_mda · as of 2026-08-13].
- Progress of pipeline candidates SCN-106 (Alteplase) and SCN-104 (DHE) through clinical development [sec_mda · as of 2026-08-13].
- Ability to raise additional capital through equity or debt to fund operations [sec_mda · as of 2026-08-13].
- Any strategic transactions or acquisitions the company may pursue [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run Scienture Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scienture Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.1 months
D/E 0.37 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$462K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 816,182 | $233K |
| geode capital management, llc | 432,186 | $123K |
| vanguard fiduciary trust co | 198,060 | $56K |
| xtx topco ltd | 47,680 | $14K |
| commonwealth equity services, llc | 44,798 | $13K |
| two sigma securities, llc | 36,445 | $10K |
| jane street group, llc | 27,636 | $8K |
| northern trust corp | 13,894 | $4K |
| citigroup inc | 5,547 | $2K |
| sbi securities co., ltd. | 55 | $16 |
Showing top 10 of 11 institutional holders of Scienture Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 6.6%
- Days to cover
- 0.3
- Shares short
- 2,223,915
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Scienture Holdings, Inc.?
Scienture Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing branded products for CNS and CVS diseases, with two launched products and a pipeline of candidates in clinical development.
Who is the CEO of Scienture Holdings, Inc.?
Dr. Shankar Hariharan Ph.D. is the chief executive officer of Scienture Holdings, Inc. (SCNX).
Where is Scienture Holdings, Inc. headquartered?
Scienture Holdings, Inc. (SCNX) is headquartered in Commack, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.